GILD
Gilead Sciences, Inc.
GILD's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over GILD overall, supported by stronger fundamentals and stronger modeled upside.
GILD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Strong | |
| Healthy |
GILD's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GILD PE Valuation
GILD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 20x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GILD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect GILD to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GILD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.55 | — |
| Q3 2026 | -$3.15 | -149% |
| Q2 2026 | -$2.66 | -153% |
| Q1 2026 | $7.35 | +54% |
| Q4 2025 | $6.78 | +1684% |
| Q3 2025 | $6.46 | +7078% |
| Q2 2025 | $5.03 | +513% |
| Q1 2025 | $4.76 | +1222% |
| Q4 2024 | $0.38 | -92% |
GILD has swung to a loss: it lost $3.15 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GILD on earnings quality, reporting a profit while its opponent remains loss making.
GILD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.3B | +6.8% |
| Q2 2026 | $7.8B | +10% |
| Q1 2026 | $7B | +4.4% |
| Q4 2025 | $7.9B | +4.7% |
| Q3 2025 | $7.8B | +3% |
| Q2 2025 | $7.1B | +1.8% |
| Q1 2025 | $6.7B | -0.3% |
| Q4 2024 | $7.6B | +6.4% |
GILD's revenue has grown year over year for six quarters in a row: $8.3B last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 42% | -1.1 points |
| Q2 2026 | -133% | -168 points |
| Q1 2026 | 37% | +3.6 points |
| Q4 2025 | 25% | -7.4 points |
| Q3 2025 | 43% | +31 points |
| Q2 2025 | 35% | -3.1 points |
| Q1 2025 | 34% | +98 points |
| Q4 2024 | 32% | +9.7 points |
GILD has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GILD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
GILD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | +21% |
| Q2 2026 | $3.4B | +377% |
| Q1 2026 | $2.4B | +47% |
| Q4 2025 | $3.1B | +10% |
| Q3 2025 | $4B | -5% |
| Q2 2025 | $720M | -40% |
| Q1 2025 | $1.7B | -22% |
| Q4 2024 | $2.8B | +45% |
GILD's free cash flow has been positive every quarter for seven years: $13.8B over the past year, up 50% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over GILD on cash flow, with more consistent year-over-year improvement.
GILD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +8M shares |
| 1 year | -0.2% | -3M shares |
| 3 years | -0.5% | -6M shares |
| 5 years | -0.9% | -11M shares |
| Available history | -2% | -26M shares |
GILD has 1.3B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $370M |
| Q2 2026 | $355M |
| Q1 2026 | $419M |
| Q4 2025 | $230M |
| Q3 2025 | $435M |
| Q2 2025 | $527M |
| Q1 2025 | $730M |
| Q4 2024 | $350M |
GILD spent $1.4B buying back its own shares over the past year, down 33% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GILD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GILD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 8.2x | High |
| Q3 2024 | 10.1x | High |
| Q2 2024 | 5.0x | High |
GILD's net debt is about 1.4 years of its operating earnings (EBITDA), down from 2.0 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GILD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 83.3 | Overbought |
GILD's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GILD PE vs Healthcare Sector
| Metric | GILD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GILD has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GILD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $158.1 | 6.3% above |
| 20 week MA | $146.4 | 15% above |
| 50 week MA | $138.9 | 21% above |
| 100 week MA | $124.2 | 35% above |
| 200 week MA | $101.1 | 66% above |
GILD is in an uptrend: it's above all five of its weekly moving averages, and 66% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
GILD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.0 | $57.1 | -13% |
| 2021 | $57.1 | $72.5 | +27% |
| 2022 | $72.5 | $84.8 | +17% |
| 2023 | $84.8 | $81.0 | -4.4% |
| 2024 | $81.0 | $94.1 | +16% |
| 2025 | $94.1 | $124.7 | +33% |
| 2026 YTD | $124.7 | $168.0 | +35% |
GILD has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.